{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"15.3","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who had a confirmed CR or PR assessed by the investigator as per modified RECIST (mRECIST) v1.1. CR. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \\<10 mm (\\<1 cm). PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with mesothelioma who had no SOC established and had experienced PD during or after at least one but no more than 2 prior regimens were included in this cohort. Participants received pegenzileukin 24 μg/kg along with pembrolizumab 200 mg via IV infusion over 30 minutes q3w on Day 1 of each cycle (each cycle is 21 days) (as 2/3L therapy), until PD, unacceptable AE or other full permanent discontinuation criteria was met or completion of Cycle 35.","id":"OG000","title":"Cohort C1:Mesothelioma:Pegenzileukin 24 μg /kg+Pembrolizumab as 2/3L Therapy"}],"paramType":"NUMBER","populationDescription":"The efficacy population consisted of all participants from the exposed population with at least one evaluable post-baseline tumor assessment or who permanently discontinued study treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment administration (Day 1) up to approximately 21 months","title":"Cohorts C1: Objective Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}